
Aridis Pharmaceuticals ARDS
Quarterly report 2023-Q3
added 11-06-2023
Aridis Pharmaceuticals Book Value 2011-2026 | ARDS
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Aridis Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -24.2 M | -13.1 M | -8.68 M | 3.64 M | 26.3 M | 11.4 M | 13.8 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 26.3 M | -24.2 M | 1.31 M |
Quarterly Book Value Aridis Pharmaceuticals
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.8 M | -24.2 M | -35.8 M | -27.9 M | -20.4 M | -13.1 M | -4.16 M | -13.5 M | -8.56 M | -8.68 M | -8.68 M | -8.68 M | -8.68 M | 3.64 M | 3.64 M | 3.64 M | 3.64 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | 11.4 M | 11.4 M | 11.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 26.3 M | -35.8 M | -1.67 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M | ||
|
Alector
ALEC
|
30.6 M | $ 2.08 | -14.4 % | $ 214 M | ||
|
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | ||
|
Altimmune
ALT
|
124 M | $ 4.2 | -2.67 % | $ 298 M | ||
|
Apellis Pharmaceuticals
APLS
|
370 M | $ 20.24 | -3.44 % | $ 2.55 B | ||
|
Aptorum Group Limited
APM
|
11.8 M | $ 0.8 | 1.87 % | $ 4.36 M | ||
|
Aprea Therapeutics
APRE
|
22.7 M | $ 0.88 | -3.72 % | $ 3.18 M | ||
|
Aptevo Therapeutics
APVO
|
4.76 M | $ 7.2 | -1.64 % | $ 1.99 M | ||
|
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M | ||
|
Aquestive Therapeutics
AQST
|
-60.2 M | $ 4.1 | 2.37 % | $ 356 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
5.36 M | - | -10.17 % | $ 12.2 K | ||
|
Arcturus Therapeutics Holdings
ARCT
|
241 M | $ 8.35 | 1.46 % | $ 225 M | ||
|
Ardelyx
ARDX
|
167 M | $ 6.37 | -2.75 % | $ 1.54 B | ||
|
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
argenx SE
ARGX
|
5.5 B | $ 756.71 | -1.33 % | $ 25 B | ||
|
Armata Pharmaceuticals
ARMP
|
-32.1 M | $ 10.91 | 1.58 % | $ 394 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
Arcutis Biotherapeutics
ARQT
|
189 M | $ 25.33 | -6.1 % | $ 3.22 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
8.32 M | - | -18.52 % | $ 27.3 M | ||
|
Artelo Biosciences
ARTL
|
-1.27 M | $ 1.15 | -3.36 % | $ 2.32 M | ||
|
Arvinas
ARVN
|
434 M | $ 12.97 | -2.3 % | $ 920 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
1.39 B | $ 61.74 | -2.42 % | $ 8.26 B | ||
|
Ascendis Pharma A/S
ASND
|
-163 M | $ 231.56 | -0.83 % | $ 5 B | ||
|
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.39 | -1.63 % | $ 8.16 B | ||
|
Actinium Pharmaceuticals
ATNM
|
32.8 M | $ 1.17 | -0.85 % | $ 35.2 M | ||
|
Atossa Therapeutics
ATOS
|
91 M | $ 4.39 | -0.9 % | $ 553 M | ||
|
Atara Biotherapeutics
ATRA
|
-97.3 M | $ 5.01 | -7.47 % | $ 37.5 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
581 M | $ 14.14 | -0.21 % | $ 1.9 B | ||
|
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | ||
|
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.68 | -1.75 % | $ 429 M | ||
|
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | ||
|
Atea Pharmaceuticals
AVIR
|
439 M | $ 4.69 | 0.21 % | $ 395 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - | ||
|
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
94.9 M | $ 4.54 | 2.44 % | $ 387 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | ||
|
Axon Enterprise
AXON
|
2.33 B | $ 570.5 | 5.18 % | $ 43.2 B | ||
|
Axsome Therapeutics
AXSM
|
88.3 M | $ 162.28 | -0.98 % | $ 8.07 B | ||
|
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | ||
|
Aytu BioScience
AYTU
|
124 M | $ 2.56 | -0.58 % | $ 16.1 M | ||
|
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | ||
|
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B |